Not Signed In - CuraGen And TopoTarget Announce Expansion Of Belinostat (PXD101) Clinical Trial In Cutaneous T-cell Lymphoma (CTCL)
Fri, 15 Dec 2006 08:00 AM EST
... CuraGen Corporation (Nasdaq: CRGN) and TopoTarget A/S announced today that the companies have reviewed interim efficacy and safety data from the ongoing open-label trial evaluating belinostat (PXD101) monotherapy for the treatment of CTCL. The observed preliminary objective response rates have met the predefined criteria for expansion of the CTCL arm of the trial. [click link for full article] ...
Related Topics
- Clinical Trials
- Lymphoma
- Non-Hodgkin's Lymphoma
- Hodgkin's Lymphoma
- Cutaneous T-Cell Lymphoma
- Cutaneous T-Cell Lymphoma, see Mycosis Fungoides and Sézary Syndrome
- Lymphoma, Cutaneous T-Cell, see Mycosis Fungoides and Sézary Syndrome
- T-Cell Lymphoma, Cutaneous, see Mycosis Fungoides and Sézary Syndrome
- Sickle Cell Anemia
- Lymphoma, Burkitt's
- Burkitt's Lymphoma
- Pharmacology
- Stem Cell Research
- Trastuzumab
- Psychopharmacology
- Small Cell Lung Cancer
- Sickle Cell
- Tarceva
- Skin Cancer
- Renal Cell Cancer
email this page
print this page
bookmark this page
feedback on this page
